$6.54
8.09% yesterday
Nasdaq, Nov 15, 09:49 pm CET
ISIN
US09077A1060
Symbol
BMEA
Sector
Industry

Biomea Fusion Inc Stock price

$6.53
-4.44 40.47% 1M
-6.71 50.68% 6M
-7.99 55.03% YTD
-2.78 29.86% 1Y
-5.15 44.09% 3Y
-12.07 64.89% 5Y
-12.07 64.89% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.58 8.16%
ISIN
US09077A1060
Symbol
BMEA
Sector
Industry

Key metrics

Market capitalization $236.64m
Enterprise Value $158.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.11
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-151.32m
Free Cash Flow (TTM) Free Cash Flow $-113.02m
Cash position $87.95m
EPS (TTM) EPS $-4.00
P/E forward negative
Short interest 38.09%
Show more

Is Biomea Fusion Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Biomea Fusion Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Biomea Fusion Inc forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Biomea Fusion Inc forecast:

Buy
80%
Hold
20%

Financial data from Biomea Fusion Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 2.35 2.35
31% 31%
-
-2.35 -2.35
31% 31%
-
- Selling and Administrative Expenses 23 23
43% 43%
-
- Research and Development Expense 124 124
34% 34%
-
-149 -149
33% 33%
-
- Depreciation and Amortization 2.35 2.35
31% 31%
-
EBIT (Operating Income) EBIT -151 -151
31% 31%
-
Net Profit -144 -144
34% 34%
-

In millions USD.

Don't miss a Thing! We will send you all news about Biomea Fusion Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biomea Fusion Inc Stock News

Neutral
GlobeNewsWire
14 days ago
REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that on November 1, 2024, the compensation c...
Neutral
GlobeNewsWire
16 days ago
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers, today presented preclinical data showing icovamenib enhanced the activity ...
Neutral
GlobeNewsWire
17 days ago
REDWOOD CITY, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers, today reported third quarter 2024 financial results and corporate highlights.
More Biomea Fusion Inc News

Company Profile

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

Head office United States
CEO Tom Butler
Employees 103
Founded 2017
Website biomeafusion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today